Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.52NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBF.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.4.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DS.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.58NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.631NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.627NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.519NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.514NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GT.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.87NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAPNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BE.1.4.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.6.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.47.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBF.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CF.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DN.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DJ.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBC.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BW.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.10.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FW.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CH.1.1.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.55NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.14NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.237NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBNNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBJ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.356NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.462NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.147NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.6 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.5 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.4 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.420NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.39.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.233NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.24NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.320NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used